Dr. Clark brings more than 15 years of experience in ophthalmology and clinical development, encompassing expertise in early and late-stage development programs, regulatory submissions, and approvals. Her impactful contributions contributed to the approval and successful launches of several pivotal retinal therapies, including Eylea, Jetrea, and Beovu.
Previously, as the Chief Medical Officer at Adverum, Dr. Clark played a pivotal role in pioneering intravitreal gene therapy for retinal diseases. In her most recent role as Vice President Clinical Development at IvericBio, an Astellas Company, she led the clinical development program that culminated in the August 2023 FDA approval of Izervay – an innovative complement inhibitor indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.
Dr. Clark earned an M.D. from Wake Forest University School of Medicine and holds a B.S. in Biology from Wake Forest University. Additionally, she earned an M.S. in Biotechnology from the Center for Biotechnology Education and Advanced Biotechnology Studies at Johns Hopkins University. Her academic achievements underscore her commitment to excellence in ophthalmology, medical research, and patient care.